Andy Hahn: Congrats to Ana Aparicio and team on this trial of 192 men with mCRPC
Andy Hahn, Genitourinary Medical Oncologist at MD Anderson Cancer Center, shared on X:
“Congratulations to Ana Aparicio and team on this adaptive, investigator-initiated trial of 192 men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) at Clinical Cancer Research! All men got 8 weeks of AAPA. Based on Prostate Specific Antigen (PSA) decline at 8 weeks, went on to add ipi, continue AAPA, or add cabazitaxel/carboplatin.
Aggressive Variant Prostate Cancer (AVPC) molecular signature was associated with worse response to AAPA at 8 weeks. And men who had unsatisfactory response to 8 weeks of AAPA had shorter survival, despite cabazitaxel/carboplatin.
Addition of ipilimumab to AAPA did not improve outcomes in Androgen Receptor (AR) -responsive mCRPC.
Exploratory bulk RNA Sequence in lymph node specimens identified subsets of macrophages enriched in the unsatisfactory group.”
Additional information
Source: Andy Hahn/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023